liver disease

  • Inside of a Gilead Sciences Lab
    April 23, 2014  

    A new drug has a 90 to 100 percent chance of curing the Hepatitis-C virus, but costs tens of thousands of dollars for a course of treatment. The announcement by the manufacturer that it earned more than $2 billion in the year’s first quarter raises the question, who should pay when drugs are highly effective, but extremely expensive? Hari Sreenivasan reports on the profits, coverage and costs. Continue reading

  • October 8, 2007  

    Since California passed a $3 billion bond measure for stem cell research, recruitment of top scientists has outpaced every other state. The new funding has sparked the building of state-of-the-art facilities and a push for stem cell innovations. Continue reading